Artificial Intelligence as a Catalyst for Novel Therapeutic Opportunities in Precision Oncology.
- 1First University Department of Respiratory Medicine, 'Sotiria' Chest Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
- 2Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Abstract
Artificial intelligence (AI) is reshaping molecular oncology by making complex biological data tractable and by extending the reach of precision drug discovery. Its emerging value is particularly evident at the interface of immunoengineering and targeted therapy, where computational models can help prioritize tumor-selective antigens, predict neoantigen immunogenicity, optimize engineered receptors, support antibody and antibody-drug conjugate design, guide small-molecule discovery, refine genome-editing strategies, and anticipate treatment response. Across these applications, the central promise is not automation for its own sake, but a wider therapeutic window in which tumor control is increased while off-target toxicity is reduced. Yet the translational gap remains substantial. Many models are still preclinical, external validation is limited, and clinical implementation remains uncommon. This Commentary follows representative methods across a therapeutic continuum that now extends from target discovery and therapeutic engineering to imaging, liquid biopsy, resistance forecasting, combination selection, and drug repurposing. We argue that clinical value will depend on closed-loop workflows in which multimodal predictions are experimentally validated, externally tested, and longitudinally updated to guide the next therapeutic decision.
Related
- Early insights into nurses' perceptions, opportunities, and concerns regarding Ambient artificial intelligence in nursing practice
- Artificial Intelligence in Pulmonary Hypertension: Advancements, Opportunities, and Challenges
- Current Advances in Spatial Pathology of Nasal Polyps: Challenges, Opportunities for Artificial Intelligence, and Future Directions
- Editorial: Artificial intelligence and anti-cancer drugs: advancing discovery, personalization, and precision oncology
- Toward Precision Colorectal Cancer Screening: Integrating Clinical Risk Stratification, Molecular Biomarkers, and Artificial Intelligence
BibTeX
@article{papavassiliou2026artificial,
title = {{Artificial Intelligence as a Catalyst for Novel Therapeutic Opportunities in Precision Oncology.}},
author = {Kostas A Papavassiliou and Amalia A Sofianidi and Angeliki Margoni and Athanasios G Papavassiliou},
journal = {International journal of molecular sciences},
year = {2026},
month = sep,
doi = {10.3390/ijms27198489},
url = {https://europepmc.org/article/MED/42883738},
note = {CC BY},
}
RIS
TY - JOUR
TI - Artificial Intelligence as a Catalyst for Novel Therapeutic Opportunities in Precision Oncology.
AU - Kostas A Papavassiliou
AU - Amalia A Sofianidi
AU - Angeliki Margoni
AU - Athanasios G Papavassiliou
PY - 2026
DA - 2026/09/23
JO - International journal of molecular sciences
DO - 10.3390/ijms27198489
UR - https://europepmc.org/article/MED/42883738
AB - Artificial intelligence (AI) is reshaping molecular oncology by making complex biological data tractable and by extending the reach of precision drug discovery. Its emerging value is particularly evident at the interface of immunoengineering and targeted therapy, where computational models can help prioritize tumor-selective antigens, predict neoantigen immunogenicity, optimize engineered receptors, support antibody and antibody-drug conjugate design, guide small-molecule discovery, refine genome-editing strategies, and anticipate treatment response. Across these applications, the central promise is not automation for its own sake, but a wider therapeutic window in which tumor control is increased while off-target toxicity is reduced. Yet the translational gap remains substantial. Many models are still preclinical, external validation is limited, and clinical implementation remains uncommon. This Commentary follows representative methods across a therapeutic continuum that now extends from target discovery and therapeutic engineering to imaging, liquid biopsy, resistance forecasting, combination selection, and drug repurposing. We argue that clinical value will depend on closed-loop workflows in which multimodal predictions are experimentally validated, externally tested, and longitudinally updated to guide the next therapeutic decision.
SN - 1422-0067
ER -